BMS-986340

DRUG2 trials

Sponsors

Bristol-Myers Squibb, M.D. Anderson Cancer Center

Conditions

BevacizumabCarcinoma, Renal CellCervical CancerGastric/Gastroesophageal Junction AdenocarcinomaMelanomaMicrosatellite Stable Colorectal CancerMicrosatellite-stable Colorectal CancerNivolumab

Phase 1

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

RecruitingNCT04895709

Bristol-Myers SquibbCarcinoma, Renal Cell, Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma +8

Start: 2021-05-27End: 2031-08-31Target: 1109Updated: 2026-08-17

Phase 2

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

SuspendedNCT07011550

M.D. Anderson Cancer CenterBevacizumab, Microsatellite-stable Colorectal Cancer, Nivolumab +1

Start: 2025-08-15End: 2030-07-01Updated: 2026-08-25